Getmedicin.org

Codeine Phosphate Oral Solution





CODEINE PHOSPHATE ORAL SOLUTION B.P

5/8/2014
03:56 | Author: Hannah Ramirez

Codeine Phosphate Oral Solution
CODEINE PHOSPHATE ORAL SOLUTION B.P

Patient information for CODEINE PHOSPHATE ORAL SOLUTION B.P. Including dosage instructions and possible side effects.

We comply with the HONcode standard for trustworthy health information. Verify here.

Data sources include Micromedex (updated Sep 26th, 2014), Cerner Multum (updated Oct 16th, 2014), Wolters Kluwer (updated Oct 9th, 2014) and others. To view content sources and attributions, refer to our editorial policy.

Follow: Google+ Facebook Twitter YouTube RSS.

Source: Medicines and Healthcare Products Regulatory Agency.

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist. More FDA updates.

Active substance: CODEINE PHOSPHATE Expand view ⇕

provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment.

Terms of Use · Privacy Policy.

Comments (0)



Codeine Phosphate Syrup - SPC - eMC

11/17/2014
05:28 | Author: Hannah Ramirez

Codeine Phosphate Oral Solution
Codeine Phosphate Syrup - SPC - eMC

Oral Solution. A clear almost colourless syrupy liquid. top. 4. Clinical particulars. top. 4.1 Therapeutic indications. 1. For the relief of the symptoms of diarrhoea in.

Codeine is not recommended for use in children in whom respiratory function might be compromised including neuromuscular disorders, severe cardiac or respiratory conditions, upper respiratory or lung infections, multiple trauma or extensive surgical procedures. These factors may worsen symptoms of morphine toxicity.

Comments (2)Read more

Acetaminophen codeine phosphate oral solution usp - Contract

11/16/2014
03:08 | Author: Alex Watson

Tylenol codeine elixir
Acetaminophen codeine phosphate oral solution usp - Contract

ACETAMINOPHEN & CODEINE PHOSPHATE ORAL SOLUTION USP 120 mg/12 mg/5mL, CV. Compare to: Tylenol w/Codeine. Product Insert · Material Safety.

Comments (0)

Compound Codeine Phosphate Oral Solution-Aoxing

9/15/2014
01:36 | Author: Emily Peterson

Tylenol codeine elixir
Compound Codeine Phosphate Oral Solution-Aoxing

Product Classification. Approved Products · Narcotic Pipeline Products. Product Classification. Compound Codeine Phosphate Oral Solution. Back:Tilidine &.

Comments (0)

Endo Pharmaceuticals - News Release - Investor Relations Solutions

7/14/2014
01:40 | Author: Alex Watson

Codeine Phosphate Oral Solution
Endo Pharmaceuticals - News Release - Investor Relations Solutions

The total sales for Acetaminophen and Codeine Phosphate Oral Solution in the U.S. for the 12 months ended September 30, 2011 were approximay $4.3.

Founded in 1983, Qualitest provides affordable, high-quality generic pharmaceuticals. Featuring a current portfolio exceeding 600 products, the company has grown significantly since its inception and is now ranked in the top ten among all suppliers of generics, based on total prescriptions filled. Qualitest is a wholly owned subsidiary of Endo Pharmaceuticals (Nasdaq: ENDP), a U.S.-based, specialty healthcare solutions company, focused on high-value branded products and specialty generics ( www.endo.com ). SOURCE Endo Pharmaceuticals.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding Endo Pharmaceuticals business which are not historical facts are "forward-looking statements" that involve risks and uncertainties. For a discussion of such risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see "Risk Factors" in the Company's Annual Report or Form 10-K for the most recently ended fiscal year.

HUNTSVILLE, Ala., Nov. 14, 2011 /PRNewswire/ -- Qualitest Pharmaceuticals today announced that the U.S. Food and Drug Administration has approved Acetaminophen and Codeine Phosphate Oral Solution USP, 120mg/12mg per 5mL.

Investors/Media: Blaine Davis/Endo, + ; Media: Kevin Wiggins/Endo, + ; Investors: Jonathan Neely/Endo, +

The total sales for Acetaminophen and Codeine Phosphate Oral Solution in the U.S. for the 12 months ended September 30, 2011 were approximay $4.3 million, according to IMS Health. About Qualitest.

Comments (0)